NEW YORK, Oct. 24 - Genomics Collaborative will provide DNA banking services and clinical research support for Cypress Bioscience to develop treatments for fibromyalgia, according to an agreement announced on Wednesday.
Terms of the deal call for GCI to help collect, process, and store DNA and cerebrospinal fluid collected from fibromyalgia patients. The functional genomics company may also provide control samples from its own database for a patient registry that is being developed by Cypress.
Financial details of the agreement were not disclosed.
San Diego-based Cypress is focused on the treatment of rheumatological and blood platelet disorders. Its patient registry will combine genetic data with phenotypic information like treatment histories and quality-of-life reports.
GCI, based in Cambridge, Mass., maintains a DNA database of more than 100,000 patients. The repository links DNA, tissue, and sera samples with detailed epidemiological, patient, and treatment data, and includes clinical research material for cardiovascular and inflammatory diseases, metabolic disorders, and cancer, according to GCI.
Fibromyalgia syndrome, estimated to affect between 2 percent and 4 percent of the population in the United States, is a poorly understood chronic condition characterized by incapacitating fatigue, pain, and stiffness. The disease may also have a genetic component. According to Cypress, its is the first genomics research initiative into the disorder.